Strong Market Position AMILI is the leading precision gut microbiome company in Southeast Asia with a robust database and unique microbiome transplant bank, providing a competitive edge for expanding microbiome-based therapies and diagnostics in the region.

Recent Funding Boost The company secured substantial investment from East Ventures and a Series A funding of 10.5 million USD, supporting growth initiatives and expanding service offerings, creating opportunities for partners involved in healthcare innovation and biotech investments.

Strategic Partnerships Partnerships with healthcare providers like Cordlife indicate a strong channel for launching new microbiome banking and related services, opening avenues for collaboration with hospitals and biotech firms seeking microbiome solutions.

Innovation Focus AMILI’s advanced platform captures detailed insights into gut microbiome health, presenting opportunities to engage health professionals and wellness companies interested in personalized gut health management and preventative healthcare markets.

Market Expansion Potential With current revenue estimates between 10 to 25 million USD and a focus on Southeast and Greater Asia, there is significant scope for sales efforts targeting healthcare organizations, insurers, and biotech startups looking to leverage microbiome science for new product development.